A post by @FirstSquawk on X.
US FDA GRANTS APPROVAL TO GAZYVA FOR ADULTS WITH PRIMARY MEMBRANOUS NEPHROPATHY.
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
The U.S. FDA approved Gazyva for adults with primary membranous nephropathy. The decision marks a new regulatory milestone for the Roche drug in a kidney disease indication. It matters because it expands Gazyva's label beyond its existing uses and gives patients a newly sanctioned treatment option. Watch for Roche's pricing and launch details, plus any update to peak sales estimates.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Gazyva, US FDA, Primary Membranous Nephropathy